Susan Schniepp, VP of Quality at OSO BioPharmaceuticals, Elected to PDA Board of Directors
Albuquerque, NM, January 28, 2011 --(PR.com)-- Susan Schniepp, vice president of quality at OSO BioPharmaceuticals Manufacturing, LLC, has been elected to the board of directors at the Parenteral Drug Association (PDA).
Schniepp has enjoyed a long and productive relationship with the PDA. In addition to serving on numerous committees and being a featured speaker at events, she received the PDA’s Distinguished Author Award for her book, Understanding the United States Pharmacopeia and the National Formulary: Demystifying the Standards-Setting Process.
Schniepp also received the PDA’s Distinguished Service Award in 2008 and its Gordon Personeus Award in 2010, which honors a long-time member for noteworthy contributions to the organization.
“Sue is a shining star within our industry for her unflagging commitment to high quality and her willingness to share her knowledge and experience with others,” said Stuart Rose, president and CEO of OsoBio. “Serving on the PDA board affords Susan yet another opportunity to spread the quality message and lead by example.”
In managing all operational quality-related issues for OsoBio, Schniepp is responsible for cGMP compliance of facilities. Quality-related matters concerning validation as well as regulatory affairs, records and filings also fall under her scope of responsibility.
Recently, Schniepp served as chairwoman of the Monograph Development-Psychiatrics and Psychoactives Expert Committee for United States Pharmacopeia (USP), a non–governmental, official public standards-setting authority for prescription and over–the–counter medicines and other health-care products manufactured or sold in the United States. USP standards for quality, purity, strength and consistency are recognized and used in more than 130 countries.
As the first woman appointed to serve on the editorial advisory board of Pharmaceutical Technology magazine, Schniepp writes the publication’s quarterly column, “Inside Standards.”
Schniepp’s term on the PDA board of directors is for two years.
PDA was founded in 1946 by a small group of pharmaceutical manufacturers who recognized the need to disseminate technical information within the industry. Today, with more than 10,000 members worldwide, PDA is the recognized authoritative voice and leading technical organization in the field of parenteral science and technology.
OSO BioPharmaceuticals Manufacturing, LLC, is a contract manufacturing organization (CMO) focusing on biologic and pharmaceutical injectables.
Headquartered in Albuquerque, N.M., OsoBio specializes in products requiring complex handling, including highly potent compounds. Responsiveness, attention to detail and clear communication are the hallmarks of our client care.
OsoBio surpasses quality-assurance expectations within our industry. Our employees are industry veterans who provide innovative solutions to our clients’ most difficult projects.
Contact: Milton Boyer, VP business development and sales, 706.694.2514
###
Schniepp has enjoyed a long and productive relationship with the PDA. In addition to serving on numerous committees and being a featured speaker at events, she received the PDA’s Distinguished Author Award for her book, Understanding the United States Pharmacopeia and the National Formulary: Demystifying the Standards-Setting Process.
Schniepp also received the PDA’s Distinguished Service Award in 2008 and its Gordon Personeus Award in 2010, which honors a long-time member for noteworthy contributions to the organization.
“Sue is a shining star within our industry for her unflagging commitment to high quality and her willingness to share her knowledge and experience with others,” said Stuart Rose, president and CEO of OsoBio. “Serving on the PDA board affords Susan yet another opportunity to spread the quality message and lead by example.”
In managing all operational quality-related issues for OsoBio, Schniepp is responsible for cGMP compliance of facilities. Quality-related matters concerning validation as well as regulatory affairs, records and filings also fall under her scope of responsibility.
Recently, Schniepp served as chairwoman of the Monograph Development-Psychiatrics and Psychoactives Expert Committee for United States Pharmacopeia (USP), a non–governmental, official public standards-setting authority for prescription and over–the–counter medicines and other health-care products manufactured or sold in the United States. USP standards for quality, purity, strength and consistency are recognized and used in more than 130 countries.
As the first woman appointed to serve on the editorial advisory board of Pharmaceutical Technology magazine, Schniepp writes the publication’s quarterly column, “Inside Standards.”
Schniepp’s term on the PDA board of directors is for two years.
PDA was founded in 1946 by a small group of pharmaceutical manufacturers who recognized the need to disseminate technical information within the industry. Today, with more than 10,000 members worldwide, PDA is the recognized authoritative voice and leading technical organization in the field of parenteral science and technology.
OSO BioPharmaceuticals Manufacturing, LLC, is a contract manufacturing organization (CMO) focusing on biologic and pharmaceutical injectables.
Headquartered in Albuquerque, N.M., OsoBio specializes in products requiring complex handling, including highly potent compounds. Responsiveness, attention to detail and clear communication are the hallmarks of our client care.
OsoBio surpasses quality-assurance expectations within our industry. Our employees are industry veterans who provide innovative solutions to our clients’ most difficult projects.
Contact: Milton Boyer, VP business development and sales, 706.694.2514
###
Contact
Sinclair & Co.
Karen Stinneford
919-833-9102
Karen Stinneford
919-833-9102
Contact
Categories